-
Analyst Opinions
NewMobile World Congress (MWC) 2024 – Startups Race for Digital Change
Mobile World Congress (MWC) 2024 Report Overview MWC (Mobile World Congress) is a premier global event for the mobile technology industry, while 4YFN (4 Years from Now) is its associated platform focusing on connecting startups with investors and partners to drive innovation. With over 40 companies in attendance, AI startups took center stage at MWC 2024, signaling robust investor and market interest in AI as the key driver for future innovation. Beyond AI, fintech, digitalization, IoT, digital media, and health...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SBT-101 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBT-101 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBT-101 in Breast Cancer Drug Details: SBT-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Systolic Heart Failure Drug Details: KER-012 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Diastolic Heart Failure (HFpEF) Drug Details: KER-012 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-065 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-065 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-065 in Obesity Drug Details: KER-065 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-065 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-065 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-065 in Duchenne Muscular Dystrophy Drug Details: KER-065 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteogenesis Imperfecta report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteogenesis Imperfecta Drug Details: KER-012 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteoporosis Drug Details: KER-012 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICG-136 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICG-136 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICG-136 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target PD-L1 For Oncology in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target PD-L1 For Oncology in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target PD-L1...